YP1A Stock Overview
A late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Immutep Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$1.76 |
| 52 Week High | AU$3.00 |
| 52 Week Low | AU$1.54 |
| Beta | 1.92 |
| 11 Month Change | -0.56% |
| 3 Month Change | -16.98% |
| 1 Year Change | 3.53% |
| 33 Year Change | -43.23% |
| 5 Year Change | 17.33% |
| Change since IPO | 16.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| YP1A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -13.7% | 0.8% | -0.4% |
| 1Y | 3.5% | -16.7% | 7.1% |
Return vs Industry: YP1A exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: YP1A exceeded the German Market which returned 7.8% over the past year.
Price Volatility
| YP1A volatility | |
|---|---|
| YP1A Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: YP1A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: YP1A's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | Marc Voigt | www.immutep.com |
Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma.
Immutep Limited Fundamentals Summary
| YP1A fundamental statistics | |
|---|---|
| Market cap | €257.61m |
| Earnings (TTM) | -€26.54m |
| Revenue (TTM) | €2.39m |
107.9x
P/S Ratio-9.7x
P/E RatioIs YP1A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YP1A income statement (TTM) | |
|---|---|
| Revenue | AU$3.84m |
| Cost of Revenue | AU$41.55m |
| Gross Profit | -AU$37.70m |
| Other Expenses | AU$5.01m |
| Earnings | -AU$42.72m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.029 |
| Gross Margin | -981.42% |
| Net Profit Margin | -1,111.87% |
| Debt/Equity Ratio | 0.5% |
How did YP1A perform over the long term?
See historical performance and comparison